Founder and CEO for LipidEra Therapeutics

CEO for LipidEra Therapeutics

Currently, statin treatment is the gold standard for lowering LDL cholesterol. However, 6-10% of patients develop resistance to high-dose statins and must rely on add-on therapies that often lack high efficacy.

LipidEra aims to change this by developing and marketing a second-line treatment with superior efficacy. This innovative solution promises to significantly impact a large group of patients and benefit society as a whole.

The invention.
The research team from Charles University and IOCB Prague has developed a groundbreaking small molecule with a novel dual mechanism of action, poised to lower LDL cholesterol in statin-intolerant heterozygous hypercholesterolemia patients and address other related metabolic disorders. This affordable and innovative solution has already demonstrated outstanding results in animal studies. We are seeking a visionary entrepreneur to lead the charge and bring this promising treatment to market.

Seize this opportunity to make a significant impact in the field of metabolic diseases!

The position of CEO
We are looking for a driven CEO who will be responsible for developing and executing the overall business strategy, actively supported by NLC and partnering with the inventor and other strategic partners. 

Responsibilities include: 

• Fundraise for early stage biotech assets
• Design the overall business strategy 
• Ensure the strategy gets executed efficiently by selecting the right pharma partners and actively managing relationships, projects and processes.
• Develop patent strategy for early stage biotech company
• Building a network in the cardiometabolic space

Your profile

You are highly motivated to make patient impact and commercially develop an early-stage novel drug. You are often described as;

• a dynamic strategist with a talent for crafting and executing commercial strategies for innovative products. We're looking for someone with a proven track record in demonstrating treatment superiority and a robust network in metabolic diseases, including hypercholesterolemia, and cardio-metabolic conditions, to take on the challenge of competing in the statin market. 

• A connector with strong networking and influencing ability at all levels of seniority in the therapeutics field.
• Excellent communication skills, including presentation and negotiation skills.

Your track record includes: 

• Experience in multi-million fundraising, ideally with both non-dilutive and dilutive funding
• Experience with preclinical studies and IND filing
• M&A experience is also considered a plus

The opportunity

We offer the unique opportunity to an entrepreneur or executive with entrepreneurial ambition to come on board as a co-founder in a highly promising venture. The participation package includes:

• Equity-based remuneration
• Cash compensation tied to successful funding of the company
• The opportunity to co-fund at a favourable valuation

As a NLC venture CEO you will have access to the expertise and network of the entire NLC ecosystem including the use of NLC Venture Services and of course you’ll join the supportive group of CEO’s leading our other (100 ) ventures.

Last but not least

As a CEO for LipidEra Therapeutics, you will have the unique opportunity to lead the charge in bringing a groundbreaking small molecule treatment to market, offering a superior second-line solution for statin-resistant patients, and making a significant impact on the health and well-being of countless individuals and society as a whole.

If you have any questions please contact Wijna Bekker, wijna.bekker@nlc.health

#LI-WB1